Overview

Lower Dose Depo Provera® Contraceptive Injection

Status:
Completed
Trial end date:
2018-05-15
Target enrollment:
Participant gender:
Summary
This is a randomized, partially-blinded, multi-center, parallel-group study to evaluate and compare the PD and PK of MPA after a single SC injection of either 45 mg/0.3 mL, 75 mg/0.5 mL or 105 mg/0.7 mL of Depo-Provera CI, and one cycle of Depo-subQ 104 use when injected in the abdomen, in women of reproductive age with confirmed ovulatory baseline cycle
Phase:
Phase 1
Details
Lead Sponsor:
FHI 360
Treatments:
Contraceptive Agents
Medroxyprogesterone
Medroxyprogesterone Acetate